{"public_id":"co_5d3d8231143634eac6c44d747ac875c9","status":"active","merged_into_public_id":null,"resolved_public_id":"co_5d3d8231143634eac6c44d747ac875c9","name":"cardiovascular risk","description":"The baseline risk of cardiovascular events in patients receiving antiplatelet therapy.","aliases":[],"types":["risk factor"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":32544246,"title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.","citation_count":728,"url":"https://sah.borca.ai/papers/32544246"}],"claims":[{"public_id":"cl_7139a125a9499c3fe3d3c46f44c4b04d","text":"Concurrent ibuprofen may limit the cardioprotective effects of aspirin in patients with increased cardiovascular risk.","corpus_id":32544246,"url":"https://sah.borca.ai/claims/cl_7139a125a9499c3fe3d3c46f44c4b04d"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_5d3d8231143634eac6c44d747ac875c9","url":"https://sah.borca.ai/concepts/co_5d3d8231143634eac6c44d747ac875c9"}